Deluxe Family(SH:600503) Zheng Quan Zhi Xing·2025-08-10 13:14Core Viewpoint - The audit report for Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. indicates that the financial statements fairly reflect the company's financial position and operating results for the periods ending December 31, 2024, and February 28, 2025, in accordance with accounting standards [3][4]. Financial Performance - The company's operating revenue for the year 2024 and the first two months of 2025 was reported at RMB 32,267.25 million, with growth rates of 80.89% and 89.24% respectively [4][5]. Audit Opinion - The audit firm, Zhongxinghua Certified Public Accountants LLP, concluded that the financial statements are prepared in accordance with the relevant accounting standards and provide a true and fair view of the company's financial status [3][4]. Key Audit Matters - Revenue recognition was identified as a key audit matter due to its significance in the financial statements and the inherent risk of management manipulating revenue recognition to meet specific targets [4][5]. - The audit procedures included evaluating internal controls related to revenue recognition, sampling sales contracts, and verifying supporting documents such as invoices and payment receipts [5][6]. Management Responsibilities - The management of Haihe Pharmaceutical is responsible for preparing the financial statements in accordance with accounting standards and ensuring the effectiveness of internal controls to prevent material misstatements due to fraud or error [6][7]. Shareholder Structure - The company underwent several changes in its shareholder structure, with the latest registered capital amounting to RMB 718,243.65 million, reflecting the contributions from various investors [21][22].